Target intelligence / Profile preview

NRAS proto-oncogene GTPase (NRAS)

Target
NRAS
Molecular classification
GTPase, Small GTPase, Enzyme, Ras family protein
01

Overview

NRAS proto-oncogene GTPase is a peripheral membrane protein belonging to the Ras subfamily of small GTPases, functioning as a vital molecular switch in cellular signal transduction (UniProt, P01111). It cycles between an active GTP-bound state and an inactive GDP-bound state, a process regulated by guanine nucleotide exchange factors and GTPase-activating proteins (NCBI Gene, 4893). Once activated, NRAS stimulates downstream signaling pathways, most notably the MAPK/ERK and PI3K/AKT cascades, which are essential for regulating cell growth, differentiation, and survival (NCI Thesaurus, C17654). Somatic missense mutations, particularly at codons 12, 13, and 61, result in a protein that is locked in the active GTP-bound state, leading to continuous signaling and malignant transformation. These mutations are frequently identified in various cancers, including approximately 20% of cutaneous melanomas, as well as acute myeloid leukemia and colorectal carcinoma (StatPearls, "RAS Gene Family"). While direct inhibition of NRAS has been historically challenging due to its high nucleotide affinity, therapeutic approaches currently focus on inhibiting downstream effectors like MEK and RAF, or utilizing farnesyltransferase inhibitors to disrupt its membrane localization. Recent advancements are also seeing the emergence of direct covalent inhibitors designed to target specific mutant forms of the NRAS protein.

Other names
Neuroblastoma RAS viral oncogene homologNRAS1NS6Transforming protein N-RasGTPase NRas
02

Mechanism of action

Inhibition of downstream signaling effectors in the MAPK/ERK and PI3K/AKT pathways, inhibition of post-translational farnesylation to prevent membrane localization, and development of direct covalent inhibitors targeting specific mutant alleles.

03

Biological functions

Signal transductionCell proliferationCell survivalCell differentiationApoptosis regulation
04

Disease associations

CancerMelanomaAcute myeloid leukemiaColorectal cancerNoonan syndromeAutoimmune lymphoproliferative syndrome
05

Safety considerations

Dermatologic toxicity (e.g., rash, dermatitis)Gastrointestinal toxicity (e.g., diarrhea, nausea)Acquired resistance through bypass signaling pathwaysNarrow therapeutic index for pan-RAS inhibitionPotential for hepatotoxicity
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

NRAS Q61 mutationNRAS G12 mutationNRAS G13 mutationNRAS protein expression levelsCirculating tumor DNA (ctDNA) NRAS status

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on NRAS proto-oncogene GTPase (NRAS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRAS proto-oncogene GTPase (NRAS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call